5 Best Pharmaceutical Stocks to Buy in 2022

In this article, we discuss the 5 best pharmaceutical stocks to buy in 2022. If you want our detailed analysis of the pharmaceutical industry and these stocks, go directly to 10 Best Pharmaceutical Stocks to Buy in 2022. 

5. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 52

Based in Thousand Oaks, California, Amgen Inc. (NASDAQ:AMGN) is a multinational biopharmaceutical company that produces medicines and therapeutic biologicals for migraine, anemia, acute lymphoblastic leukemia, arthritis, osteoporosis, and asthma. 

Amgen Inc. (NASDAQ:AMGN) reported earnings for the quarter ending December 2021 on February 7, announcing EPS of $4.36, exceeding estimates by $0.35. Its $6.85 billion in revenue missed the market consensus by $22.57 million however. In 2022, the company plans to buy back $6 billion to $7 billion of its shares, including up to $6 billion worth of stock in the first quarter alone.

On December 3, Amgen Inc. (NASDAQ:AMGN) declared a $1.94 per share quarterly dividend, a 10.2% increase from its prior dividend of $1.76. With a forward yield of 3.83%, Amgen Inc. (NASDAQ:AMGN)’s dividend is payable on March 8 to shareholders of record on February 15. Amgen Inc. (NASDAQ:AMGN) has consistently increased its dividends for 10 years. 

Among the hedge funds monitored by Insider Monkey in Q4 2021, 52 funds were bullish on Amgen Inc. (NASDAQ:AMGN), unchanged from the prior quarter. John Overdeck and David Siegel’s Two Sigma Advisors is the largest stakeholder of Amgen Inc. (NASDAQ:AMGN) as of the end of 2021, with 1.81 million shares worth approximately $407 million. 

Here is what ClearBridge Sustainability Leaders Strategy had to say about Amgen, Inc. (NASDAQ:AMGN) in its Q3 2021 investor letter:

“In health care, Amgen, a biotechnology company, has endured several pipeline setbacks recently, including a slow transition of its Lumakras treatment into first-line lung cancer, a slower than expected development of its treatment for myeloma as well as the company’s asthma treatment Tezepelumab missing its primary endpoint in a Phase III study. We remain positive on the stock, with Amgen’s investments in biosimilars and its pipeline part of our long-term thesis.”